Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are widely used for the management of type 2 diabetes mellitus (T2DM) due to their metabolic and cardiovascular benefits; however, concerns have emerged regarding potential neuropsychiatric effects, including depression. Here, GLP1R is linked to major depressive disorder.